This paper is in the following e-collection/theme issue:

Breast Cancer (249) Mobile Health (mhealth) (3173) Patient-Reported Outcome Measures (PROMs) (328) mHealth for Symptom and Disease Monitoring, Chronic Disease Management (1589) Innovations and Technology in Cancer Care (466) Cancer Self-Management (70)

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54178, first published .
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Authors of this article:

Andreas Trojan1, 2 Author Orcid Image ;   Sven Roth3 Author Orcid Image ;   Ziad Atassi2 Author Orcid Image ;   Michael Kiessling2 Author Orcid Image ;   Reinhard Zenhaeusern4 Author Orcid Image ;   Yannick Kadvany5 Author Orcid Image ;   Johannes Schumacher6 Author Orcid Image ;   Gerd A Kullak-Ublick1 Author Orcid Image ;   Matti Aapro7 Author Orcid Image ;   Alexandru Eniu8 Author Orcid Image
Article Authors Cited by (1) Tweetations (2) Metrics
All Time | Last Month | Last Six Months | Last Year
JMIR Publications JMIR Publications @jmirpub

New in JMIR Cancer: Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast #cancer: Prospective Observational #study (OGIPRO) of… https://t.co/wk2WuyXphB https://t.co/eX0a4SHAyV

1:30 PM · Apr 04, 2024

1
1
JMIR Cancer JMIR Cancer @JMIR_Cancer

RT @jmirpub: New in JMIR Cancer: Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosim…

1:31 PM · Apr 04, 2024

1
1